MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancer

Table 3 Summary microRNAs used in the expression signature at each step of model development

Rank	miRNA	Chromosomal location	Validated mRNA targets	Mean squared error	Median accuracy (%)	Response^a
ER status
1	miR-342	14q32.2, intronic	-	0.132	83.3	(+)
2	miR-299-3p	14q32.31, intergenic	-	0.087	100	(-)
3	miR-217	2p16.1, intergenic	-	0.07	100	(+)
4	miR-190	15q22.2, intronic	-	0.06	100	(-)
5	miR-135b	1q32.1, intronic	-	0.057	100	(-)
6	miR-218	4p15.31, intronic	LAMB3	0.047	100	(+)
PR status
1	miR-520g	19q13.42, intergenic	-	0.186	83.3	(-)
2	miR-377	14q32.31, intergenic	-	0.129	83.3	(+)
3	miR-527-518a	19q13.42, intergenic	-	0.086	100	(-)
4	miR-520f-520c	19q13.42, intergenic	-	0.07	100	(+)
HER2/neu status
1	miR-520d	19q13.42, intergenic	-	0.109	100	(+)
2	miR-181c	19q13.12, intergenic	Tcl1	0.086	100	(-)
3	miR-302c	4q25, intronic	Cyclin D₁	0.062	100	(*)
4	miR-376b	14q32.31, intergenic	-	0.050	100	(+)
5	miR-30e-3p	1p34.2, intronic	Ubc9	0.047	100	(*)

Summary microRNAs (miRNAs) used in the expression signature at each step of model development for oestrogen receptor (ER) status, progesterone receptor (PR) status and v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors (HER2/neu) status. ^a(+), increased miRNA expression leads to increased probability of receptor positive status; (-), increased miRNA expression leads to increased probability of receptor negative status; (*), weak response, possibly interacting to modify the response of other miRNAs.

ISSN: 1465-542X